Health Canada approves Eli Lilly's daily GLP-1 weight-loss pill Foundayo
Health Canada has authorized Eli Lilly's Foundayo, a GLP-1 medication for weight loss taken as a daily pill rather than a weekly injection.
Health Canada has authorized Eli Lilly's Foundayo, a daily oral GLP-1 pill for weight loss and Type 2 diabetes treatment, with availability expected in Canadian pharmacies in January.

Health Canada has authorized Eli Lilly's Foundayo, a GLP-1 medication for weight loss taken as a daily pill rather than a weekly injection.
Foundayo is approved for adults with obesity as well as those who are overweight and have at least one related medical problem, such as high blood pressure or sleep apnea. The pill is also approved to help treat Type 2 diabetes.
Foundayo received Health Canada authorization on Nov. 13. Eli Lilly spokesperson Ethan Pigott said the company expects the pills to be available in pharmacies in January.
The active ingredient in Foundayo is orforglipron, a non-peptide GLP-1 receptor agonist. Because it is a smaller molecule than peptides semaglutide and tirzepatide, orforglipron can be taken orally and absorbed without being broken down by the digestive system, said Dr. Ehud Ur, an endocrinologist in Vancouver who is not associated with either Eli Lilly or Novo Nordisk.
"It seems to be just as good as if not better" for weight loss as semaglutide and tirzepatide, he said.
The most common side effects of GLP-1 medications — both injectable and oral — include gastrointestinal issues, such as nausea or vomiting.
Ur said whether he would prescribe Foundayo depends on the patient, partly because he is still waiting for clinical trial results on whether or not orforglipron has a cardiovascular benefit like semaglutide and tirzepatide do.
Eli Lilly also makes the injectable drugs Mounjaro and Zepbound, which contain the active ingredient tirzepatide. Tirzepatide acts on two receptors associated with insulin production and hunger: GLP-1 and GIP.
Competitor Novo Nordisk manufactures injectables Ozempic and Wegovy, which contain the active ingredient semaglutide. Semaglutide acts on GLP-1 receptors. Several other companies make generic semaglutide sold in Canada.
There is another GLP-1 pill — Novo Nordisk's Rybelsus — already on the market in Canada, but it is only approved for Type 2 diabetes management and not for weight loss.
There may soon be a second GLP-1 weight-loss pill option in Canada: competitor Novo Nordisk's Wegovy pill, which is still awaiting Health Canada approval. Both Foundayo and the Wegovy pill are approved and available in the U.S.
Foundayo is the first daily oral GLP-1 pill approved in Canada for weight loss, offering an alternative to injectable medications. Patients may prefer a pill over an injection, and the approval adds a new option to Canada's weight-loss and diabetes treatment landscape while a competing oral pill from Novo Nordisk awaits regulatory review.
Sources
This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.
The day's checked news, by email
One short email a day with the top stories. Free, and you can unsubscribe in one click.
Or follow for the latest news:
No comments yet. Start the discussion.
GE HealthCare's Critical Care Suite 3.0 received FDA 510(k) clearance to detect feeding tube placement on mobile X-ray images in adult and pediatric patients, with 99.2% sensitivity and 91.6% mean DICE localization.
Washington L&I is inspecting two Central Washington dairy farms after a Yakima County worker died Nov. 1 from avian influenza complications. A third confirmed human case was also reported.